Association between Aspartate Aminotransferase-to-Platelet Ratio Index and Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis: A Meta-Analysis of Cohort Study

Table 1

Main characteristics of the included studies.

Study (authors-year)	Region	Sample size	Hepatitis type	Follow-up period (years)	No. of HCC (%)	Cut-off value	APRI high (%)	Analysis method	HR estimation (95% CI)
Pretreatment
Song BG (2018)	Korea	1014	CHB	Median 3.9	37 (3.6)	0.5	270 (26.6)	M	2.57 (1.31-5.02)
Paik N (2018)	Korea	1006	CHB	Median 5.1	36 (3.6)	0.5	219 (21.7)	M	6.10 (2.74-13.50)
Chang KC (2018)	Taiwan	800	CHC	Median 4.46	100 (12.5)	2.57	155 (19.4)	M	2.31 (1.44-3.68)
Kim JH (2018)	Korea	924	ALC	Median 4.83	83 (9.0)	1	120 (13.0)	M	1.46 (0.73-2.94)
Nishikawa H (2017)	Japan	338	CHB	Median 4.99	33 (9.8)	0.786	188 (55.6)	M	1.13 (0.34-3.71)
Ji FP (2017)	China	34	CHC	Median 3.45	5 (14.7)	2.5	12 (35.3)	U	2.08 (1.03-4.21)
Kim JH (2016)	Korea	542	CHB	Until Sept. 2012	68 (12.5)	0.766	214 (39.5)	U	6.20 (3.32-11.58)
Lee K (2016)	Korea	598	CHC	Median 5.1	8 (1.3)	1.0	21 (3.5)	U	1.44 (1.16-1.80)
Wu CK (2016)	Taiwan	1351	CHC	Until July 2014	49(3.6)	0.7	1000 (10.0)	U	4.85 (1.51-15.60)
Ng KJ (2016)	Taiwan	105	CHC	Mean 4.38	15 (14.3)	2	52 (49.5)	M	5.55 (1.19-25.86)
Hann HW (2015)	USA	686	CHB	Median 4.37	60 (8.7)	Median	344 (50.1)	M	2.04 (1.10-3.79)
Posttreatment
Ji FP (2017)	China	34	CHC	Median 3.45	5 (14.7)	1.5	13 (38.2)	U	2.69 (1.35-5.38)
Wu CK (2016)	Taiwan	1351	CHC	Until July 2014	49(3.6)	0.7	135 (10.0)	M	2.94 (1.51-5.74)
Chen TM (non-SVR) (2016)	Taiwan	183	CHC	Median 3.07	14 (7.7)	1.5	45 (24.6)	M	10.91 (2.49-47.70)
Chen TM (SVR) (2016)	Taiwan	540	CHC	Median 3.45	15 (2.8)	0.5	121 (22.4)	M	4.40 (1.46-13.23)
Yu ML (2006)	Taiwan	776	CHC	Mean 4.75	41 (5.3)	0.75	176 (22.7)	M	5.78 (2.31-14.45)

CHB: chronic hepatitis B; CHC: chronic hepatitis C; ALC: alcoholic liver cirrhosis; M: multivariate; U: univariate; SVR: sustained virologic response; non-SVR: nonsustained virologic response.